AAAAI Foundation and Donald Y. M. Leung, MD PhD FAAAAI-JACI Lecture: Investing Together in Our Future



Dr. Donald Y. M. Leung, is the Editor-in-Chief of the Journal of Allergy and Clinical Immunology (JACI) and has served for the past 15 years. Under his leadership, the impact factor of our journal has risen from 3.7 to over 11.0, reflecting a marked improvement in publications of research dedicated to the diagnosis and treatment of allergic and immunologic diseases.

JACI is the most highly cited Journal in the field of Allergy, Asthma and Clinical Immunology and is the most visible official publication of The American Academy of Allergy, Asthma and Immunology (AAAAI).

With the recent decline in NIH funding and restrictions from other funding sources, it is critical to establish new sources of research

funding to maintain outstanding research in the field of allergy and clinical immunology. Without outstanding research, there is a threat to our specialty and our Journal. The quality of research in Allergy-Clinical Immunology could drop due to an erosion of talented researchers and clinicians in the allergy, asthma and immunology field.

Rationale for Fund Raising: Dr. Leung stepped down from his Editor-in-chief position in spring, 2015. As one of his initiatives to support and enhance research in our specialty and maintain JACI's high impact factor, he proposes to establish a new 4 million dollar research fund. The "Donald Y. M. Leung, MD, PhD-JACI Lecture" commemorates the initiation of this effort and the opportunity to advance the knowledge and/or treatment of allergy, asthma and immunology by providing a source of funding for future research.

The vision is to support quality, cutting edge translational and basic research suitable for publication in JACI and further advance patient care and the credibility of allergy/immunology". We encourage all individuals interested in securing the future of scientifically based patient care to consider donating to this exciting new funding opportunity.

The AAAAI Foundation has committed \$500,000 of dollar for dollar matching funds from within the existing corpus. This match may increase to \$1 million dollars in matching funds to create a fund of \$2 million on our way to grow \$4 million to support clinical and translational research in perpetuity. The faster we grow the fund, the quicker awards can be provided. Our vision is to have the first awards at the time Dr. Leung's term as Editor ends.

Please join the individuals who have already committed over \$300,000 to make this vision a reality. We encourage you to celebrate the contributions of Dr. Leung, the other JACI Editors and editorial staff and the success of JACI with a generous donation to the Donald Y. M. Leung-JACI Research Fund through the AAAAI Foundation website. Together we can do more.

2017 marks the 5th year of the AAAAI Foundation and Donald Y. M. Leung, MD, PhD, FAAAAI-JACI Lecture: Investing Together in Our Future award. It will be presented in Keynote Session 2701: Emerging and Re-Emerging Infectious Diseases: The Perpetual Challenge on Saturday, March 4, 2017: 3:30 to 4:30 pm, GWCC, Exhibit Hall B1.

AAAAI Foundation and Donald Y. M. Leung, MD PhD FAAAAI-JACI Lecture: Investing Together in Our Future -Anthony Fauci, MD FAAAAI



Dr. Anthony S. Fauci, M.D., is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where he oversees an extensive research portfolio devoted to preventing, diagnosing, and treating infectious and immune-mediated diseases.

Dr. Fauci has been a key advisor to five Presidents and their administrations on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza.

As an HIV/AIDS researcher he has been involved in the scientific effort since AIDS was recognized in 1981, conducting pivotal studies that underpin the current understanding of the disease and efforts to develop therapies and tools of prevention. Dr. Fauci was one of the principal architects of the President's Emergency Plan for AIDS Relief (PEPFAR), which has helped save millions of lives throughout the developing world.

Dr. Fauci is the long-time chief of the NIAID Laboratory of Immunoregulation. He has made many contributions to basic and clinical research on the pathogenesis and treatment of immunemediated and infectious diseases. He helped pioneer the field of human immunoregulation by making important basic scientific observations that underpin the current understanding of the regulation of the human immune response. In addition, Dr. Fauci is widely recognized for delineating the precise mechanisms whereby immunosuppressive agents modulate the human immune response. He developed effective therapies for formerly fatal inflammatory and immune-mediated diseases such as polyarteritis nodosa, granulomatosis with polyangiitis (formerly Wegener's granulomatosis), and lymphomatoid granulomatosis.

Dr. Fauci has made seminal contributions to the understanding of how HIV destroys the body's defenses leading to its susceptibility to deadly infections. Further, he has been instrumental in developing highly effective strategies for the therapy of patients living with HIV/AIDS, as well as for a vaccine to prevent HIV infection. He continues to devote much of his research time to identifying the nature of the immunopathogenic mechanisms of HIV infection and the scope of the body's immune responses to HIV.

Dr. Fauci is a member of the US National Academy of Sciences and the US National Academy of Medicine, and is the recipient of numerous prestigious awards for his scientific and global health accomplishments, including the National Medal of Science, the Robert Koch Medal, the Mary Woodard Lasker Award for Public Service, and the Presidential Medal of Freedom. He has been awarded 43 honorary doctoral degrees and is the author, coauthor, or editor of more than 1,290 scientific publications, including several major textbooks.